www.prnewswire.com ·
pomerantz law firm announces the filing of a class action against atara biotherapeutics inc and certain officers atra 302773073
Topic context
This topic has been covered 326827 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedThe lawsuit targets Atara Biotherapeutics, a biotech firm, alleging false statements about its lead product tabelecleucel's regulatory prospects. The negative FDA responses caused significant stock price declines, impacting investor confidence and potentially the company's ability to fund operations. The commercial mechanism is regulatory risk and litigation cost, affecting the company's margin and valuation. However, no direct impact on broader sector or supply chain is evident; the event is company-specific.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Class action lawsuit filed against Atara Biotherapeutics for alleged securities law violations.
- Lead product candidate tabelecleucel faced negative FDA responses.
- Stock price dropped 40.5% on January 16, 2025, and 56.99% on January 12, 2026.
- Class period: May 20, 2024 to January 9, 2026.
- Investor lead plaintiff deadline: May 22, 2026.
Atara Biotherapeutics' stock price is expected to drop 2-5% within 48 hours due to a class action lawsuit.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- PHARMA_BIOTECHmid
- PHARMA_BIOTECHshort
Related stories
finance.yahoo.com
transcript valneva q1 2026 earnings 155143868
aol.com
fed inflation tracker flashes warning 092000804
mondaq.com:443
weekly sanctions update may 4 2026
livemint.com
pm modi embarks on high stakes uae and europe today check full itinerary agenda petrol prices lng iran war gas 11778810712579
nwaonline.com